Myqorzo’s Balance Sheet Meets Its Biggest Catalyst
With $1.7B in cash and a Q4 sNDA plan, Cytokinetics just validated a major untreated corner of HCM.
MCK Already Compounds. This Deal Speeds It Up.
McKesson’s $2.25bn Precision deal adds clinical research heft to its fast-growing oncology segment.
Your Japan Gain Is 55%. Now the Yen Decision Gets Hard.
A BOJ hike to 1.25% changes the currency math after the Nikkei’s extraordinary run.
At $88 a Barrel, the Winners Are Not Who You Think
Falling crude is a margin gift for refiners and airlines. Here is how to hold energy exposure through the September 6 OPEC+ meeting.
Strip Out the Investment Gain. Does Claudeforce Still Hold?
Salesforce’s 23% surge deserves scrutiny on cRPO and Agentforce ARR, not the $5.90 EPS that investment gains inflated.
Diesel Cracks Tell a Different Story Than Brent
Russia’s export curbs and record refinery strikes keep diesel tight even as crude softens on Hormuz hopes.
Nvidia Beat Everything. The Margin Line Is the Trade.
Revenue of $96.2 billion and $108 billion Q3 guidance cleared every bar, but a gross-margin guide cut is where the real positioning question lives.
What Warsh Says Friday Changes the Rate Picture
A divided Fed, a hawkish dissent bloc, and a chairman who refuses to telegraph moves: here is what investors should be preparing for before he speaks.
ALB Target Cut to $140: Watch These Battery Tickers
JPMorgan cut Albemarle’s December 2027 target Tuesday as lithium prices soften. SQM, PLL, and LAC moved with it.
COIN Has a Sept. 15 Date With Congress
The CLARITY Act cloture vote is the one midterm event that could actually move Coinbase’s earnings line, not just its stock price.